Results 321 to 330 of about 39,319 (333)

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib

International Journal of Cancer, 2020
Ambrus Gáng, Donát Alpár, Seyed Farhad Saberali   +2 more
exaly  

Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies

Journal of Thrombosis and Haemostasis, 2017
Joseph J Shatzel, Owen J T Mccarty
exaly  

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

Cancer, 2015
Susan M O'brien, William G Wierda, Francesco C Stingo   +2 more
exaly  

Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies

European Journal of Haematology, 2018
Benjamin F Tillman, Jeremy L Warner
exaly  

Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

Cancer, 2017
Susan M O'brien, Preetesh Jain, Philip A Thompson   +2 more
exaly  

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects

British Journal of Haematology, 2018
Oshrat Hershkovitz-rokah, D D’enterria
exaly  

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2019
C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Šimkovič, O. Samoilova, J. Novak, D. Ben-yehuda, V. Strugov, D. Gill, J. Gribben, E. Hsu, C. Lih, Cathy Zhou, F. Clow, D. James, L. Styles, I. Flinn   +19 more
semanticscholar   +1 more source

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

British Journal of Haematology, 2018
Preetesh Jain, Rashmi Kanagal-shamanna, Shaojun Zhang   +2 more
exaly  

Ibrutinib in der Langzeitbetrachtung [PDF]

Info Onkologie, 2016
openaire   +1 more source

Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study

Mycoses, 2019
Tamar Lachish, Ronen Ben-ami, Jennifer R Brown   +2 more
exaly